Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Matched Control Feasibility Study to Determine the Capacity of the Onco-Seraph 100 Microbind® Affinity Blood Filter ( ONCObind Procedure) to Remove Circulating Tumor Cells From the Blood in Patients With Either Metastatic Pancreatic Adenocarcinoma or Metastatic Colorectal Carcinoma

NCT06655142 is registered in ClinicalTrials.gov with ExThera Medical Corporation as lead sponsor.

NCT NCT06655142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06655142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Matched Control Feasibility Study to Determine the Capacity of the Onco-Seraph 100 Microbind® Affinity Blood Filter ( ONCObind Procedure) to Remove Circulating Tumor Cells From the Blood in Patients With Either Metastatic Pancreatic Adenocarcinoma or Metastatic Colorectal Carcinoma
Lead sponsor
ExThera Medical Corporation
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 15, 2027
Completion date
July 31, 2028
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal carcinoma (mcrc), pancreatic ductal adenocarcinoma (mpdac)